亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial

医学 临床终点 减肥 人口 随机对照试验 意向治疗分析 肥胖 内科学 临床试验 前瞻性队列研究 物理疗法 环境卫生
作者
Barham K. Abu Dayyeh,Fateh Bazerbachi,Eric J. Vargas,Reem Z. Sharaiha,Christopher C. Thompson,Bradley C Thaemert,André Teixeira,Christopher G. Chapman,Vivek Kumbhari,Michael Ujiki,Jeanette E. Ahrens,Courtney N. Day,Andrés Acosta,Dilhana Badurdeen,Navtej Buttar,Matthew M. Clark,Laura Eaton,Omar M. Ghanem,Karen Grothe,Pichamol Jirapinyo
出处
期刊:The Lancet [Elsevier BV]
卷期号:400 (10350): 441-451 被引量:329
标识
DOI:10.1016/s0140-6736(22)01280-6
摘要

Summary

Background

Endoscopic sleeve gastroplasty (ESG) is an endolumenal, organ-sparing therapy for obesity, with wide global adoption. We aimed to explore the efficacy and safety of ESG with lifestyle modifications compared with lifestyle modifications alone.

Methods

We conducted a randomised clinical trial at nine US centres, enrolling individuals aged 21–65 years with class 1 or class 2 obesity and who agreed to comply with lifelong dietary restrictions. Participants were randomly assigned (1:1·5; with stratified permuted blocks) to ESG with lifestyle modifications (ESG group) or lifestyle modifications alone (control group), with potential retightening or crossover to ESG, respectively, at 52 weeks. Lifestyle modifications included a low-calorie diet and physical activity. Participants in the primary ESG group were followed up for 104 weeks. The primary endpoint at 52 weeks was the percentage of excess weight loss (EWL), with excess weight being that over the ideal weight for a BMI of 25 kg/m2. Secondary endpoints included change in metabolic comorbidities between the groups. We used multiple imputed intention-to-treat analyses with mixed-effects models. Our analyses were done on a per-protocol basis and a modified intention-to-treat basis. The safety population was defined as all participants who underwent ESG (both primary and crossover ESG) up to 52 weeks.

Findings

Between Dec 20, 2017, and June 14, 2019, 209 participants were randomly assigned to ESG (n=85) or to control (n=124). At 52 weeks, the primary endpoint of mean percentage of EWL was 49·2% (SD 32·0) for the ESG group and 3·2% (18·6) for the control group (p<0·0001). Mean percentage of total bodyweight loss was 13·6% (8·0) for the ESG group and 0·8% (5·0) for the control group (p<0·0001), and 59 (77%) of 77 participants in the ESG group reached 25% or more of EWL at 52 weeks compared with 13 (12%) of 110 in the control group (p<0·0001). At 52 weeks, 41 (80%) of 51 participants in the ESG group had an improvement in one or more metabolic comorbidities, whereas six (12%) worsened, compared with the control group in which 28 (45%) of 62 participants had similar improvement, whereas 31 (50%) worsened. At 104 weeks, 41 (68%) of 60 participants in the ESG group maintained 25% or more of EWL. ESG-related serious adverse events occurred in three (2%) of 131 participants, without mortality or need for intensive care or surgery.

Interpretation

ESG is a safe intervention that resulted in significant weight loss, maintained at 104 weeks, with important improvements in metabolic comorbidities. ESG should be considered as a synergistic weight loss intervention for patients with class 1 or class 2 obesity. This trial is registered with ClinicalTrials.gov, NCT03406975.

Funding

Apollo Endosurgery, Mayo Clinic.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
丸子完成签到 ,获得积分10
2秒前
科研通AI6.4的应助被amiee采纳,获得10
3秒前
yangzai完成签到 ,获得积分0
6秒前
11秒前
31秒前
朝与暮完成签到,获得积分10
33秒前
42秒前
49秒前
49秒前
顾矜的应助被雪白的听寒采纳,获得10
55秒前
55秒前
may发布了新的文献求助10
56秒前
深情安青的应助被昏睡的映阳采纳,获得10
1分钟前
1分钟前
Nobodyet发布了新的文献求助10
1分钟前
迷人白桃完成签到,获得积分10
1分钟前
科研通AI2S的应助被小邹采纳,获得10
1分钟前
Wd完成签到,获得积分10
1分钟前
1分钟前
1分钟前
YUAN完成签到,获得积分10
1分钟前
SunJay完成签到 ,获得积分10
1分钟前
文艺夜白完成签到,获得积分10
1分钟前
程生完成签到,获得积分10
2分钟前
小貉完成签到,获得积分10
2分钟前
2分钟前
小邹发布了新的文献求助10
2分钟前
fpy完成签到,获得积分10
2分钟前
wx完成签到,获得积分10
2分钟前
清爽老九发布了新的文献求助10
2分钟前
2分钟前
单纯寄云完成签到,获得积分10
2分钟前
澹青云完成签到 ,获得积分10
2分钟前
清爽老九完成签到,获得积分0
2分钟前
Nobodyet完成签到,获得积分10
2分钟前
江蹇完成签到,获得积分10
2分钟前
深情安青的应助被小邹采纳,获得10
3分钟前
1874发布了新的文献求助100
3分钟前
受不了12345完成签到,获得积分10
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190113
求助须知:如何正确求助?哪些是违规求助? 9577216
关于积分的说明 21852162
捐赠科研通 7788317
什么是DOI,文献DOI怎么找? 3436259
关于科研通互助平台的介绍 2559990
邀请新用户注册赠送积分活动 2482862